Hormone replacement in menopause must be evaluated thoroughly on an individual basis with careful attention to the important benefits and risks. This includes of course objective measurements of bioactive hormone levels before and during hormone replacement at appropriate intervals, including analysis of benign versus troublesome estrogen metabolites. Regarding adverse effects that must be weighed, an important study just published in The Lancet brings to light a significant risk for ovarian cancer in current and past users of hormone replacement.